Our projects

MINTAKA - PMS (Therapeutics, Innovative Therapies)

Sponsor : Hoffmann-La Roche 

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis

RHU PRIMUS (WP6) - RMS

(Medical device)
Sponsor : CHU de Nantes

Real-life study of the multiple impacts of using a medical decision support tool in relapsing-remitting multiple sclerosis.

• Press Release 

MUSICALISE - RMS, PMS

(Optimizing quality of life)

Sponsor : Assistance Publique - Hôpitaux de Paris

Project aimed at developing a cutting-edge, high-performance interdisciplinary care model that optimizes the integration of care provided to people with MS and, consequently, the overall quality of care.

SPAM 3 - RMS, RIS (Biomarkers)

Sponsor : CHU de Nice

Comparison of Digital Biomarkers in Subjects With Radiologically Isolated Syndrome (RIS) and Multiple Sclerosis (MS) Patients With Clinically Normal Neurological Examination

PHRC MYTH MS - RMS, SPMS

(Knowledge enhancement)
Sponsor : CHU de Strasbourg 

Multicenter, prospective study analyzing the occurrence of MS relapses without radiological evidence, with the aim of characterizing the proportion of patients with RRMS who experience a relapse without gadolinium-enhancing lesions on early brain and spinal cord MRI.

PHRC TRAIN -  neuromyelitis optica

(Therapeutics, rare inflammatory diseases)
Sponsor : CHU de Strasbourg 

Treatment with Ravulizumab vs. plasma exchange after an episode of myelitis and/or optic neuritis (initial or relapse) in patients with neuromyelitis optica 

FREVIVA - SPMS (Therapeutics, Innovative therapies)

Sponsor : Sanofi 

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

TOTEM RMS - RMS (Therapeutics, Remyelination/Neuroprotection)

Sponsor : CHU de Strasbourg

TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

CAR-T CYTB323N12101 -  RMS (Thérapeutics, Innovative therapies)

Sponsor : Novartis Pharmaceuticals

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

RESHAPE - RMS (Therapeutics, Innovative therapies)

Sponsor: Novartis Pharmaceuticals

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

MOGwAI - MOGAD (Therapeutics, Rare inflammatory diseases)

Sponsor : Hospices Civils de Lyon

A Randomized, Placebo-controlled Phase 3 Trial of Azathioprine for the Prevention of Relapse in Myelin-oligodendrocyte-glycoprotein (MOG)-Antibody Associated Disease

WINDOCRE - RMS, SPMS (Therapeutics, Therapeutic Management)

Sponsor : Fondation Ophtalmologique Adolphe de Rothschild

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

PHRC TWINS - RMS (Therapeutics, Therapeutic Management)

Sponsor : CHU de Strasbourg

Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over.

LTS17043 - PMS, RMS (Therapeutics, Innovative Therapies)

Sponsor : Sanofi

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.